These integrated findings underscore the beneficial immune microenvironment in LTS HGG driven by specific innate and adaptive immune components. This immune signature may serve as a prognostic indicator and guide immunomodulatory therapeutic strategies for gliomas.
Patanè et al. (2026) studied this question.